Towards Precritical Medical Therapy of the Abdominal Aortic Aneurysm

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2022 Dec 23

PMID 36551822

Authors

Lucia Musumeci

Wolf Eilenberg

Joel Pincemail

Koichi Yoshimura

Natzi Sakalihasan

Affiliations

Soon will be listed here.

Abstract

Pharmacotherapy for abdominal aortic aneurysm (AAA) can be useful for prevention, especially in people at higher risk, for slowing down AAA progression, as well as for post-surgery adjuvant treatment. Our review focuses on novel pharmacotherapy approaches targeted towards slowing down progression of AAA, known also as secondary prevention therapy. Guidelines for AAA are not specific to slow down the expansion rate of an abdominal aortic aneurysm, and therefore no medical therapy is recommended. New ideas are urgently needed to develop a novel medical therapy. We are hopeful that in the future, pharmacologic treatment will play a key role in the prevention and treatment of AAA.

References

Fontana P, Zufferey A, Daali Y, Reny J . Antiplatelet therapy: targeting the TxA2 pathway. J Cardiovasc Transl Res. 2013; 7(1):29-38. DOI: 10.1007/s12265-013-9529-1. View

Michel J, Martin-Ventura J, Egido J, Sakalihasan N, Treska V, Lindholt J . Novel aspects of the pathogenesis of aneurysms of the abdominal aorta in humans. Cardiovasc Res. 2010; 90(1):18-27. PMC: 3058728. DOI: 10.1093/cvr/cvq337. View

Liu H, Wei P, Fu W, Xia C, Li Y, Tian K . Dapagliflozin Ameliorates the Formation and Progression of Experimental Abdominal Aortic Aneurysms by Reducing Aortic Inflammation in Mice. Oxid Med Cell Longev. 2022; 2022:8502059. PMC: 8816542. DOI: 10.1155/2022/8502059. View

Cyrus T, Yao Y, Ding T, Dogne J, Pratico D . Thromboxane receptor blockade improves the antiatherogenic effect of thromboxane A2 suppression in LDLR KO mice. Blood. 2006; 109(8):3291-6. PMC: 1852239. DOI: 10.1182/blood-2006-08-044990. View

Yoshimura K, Morikage N, Nishino-Fujimoto S, Furutani A, Shirasawa B, Hamano K . Current Status and Perspectives on Pharmacologic Therapy for Abdominal Aortic Aneurysm. Curr Drug Targets. 2017; 19(11):1265-1275. PMC: 6182934. DOI: 10.2174/1389450119666171227223331. View

Wang H, Li T, Chen S, Gu Y, Ye S . Neutrophil Extracellular Trap Mitochondrial DNA and Its Autoantibody in Systemic Lupus Erythematosus and a Proof-of-Concept Trial of Metformin. Arthritis Rheumatol. 2015; 67(12):3190-200. DOI: 10.1002/art.39296. View

Pincemail J, Defraigne J, Courtois A, Albert A, Cheramy-Bien J, Sakalihasan N . Abdominal Aortic Aneurysm (AAA): Is There a Role for the Prevention and Therapy Using Antioxidants?. Curr Drug Targets. 2017; 19(11):1256-1264. DOI: 10.2174/1389450118666170918164601. View

Hussain T, Tan B, Yin Y, Blachier F, Tossou M, Rahu N . Oxidative Stress and Inflammation: What Polyphenols Can Do for Us?. Oxid Med Cell Longev. 2016; 2016:7432797. PMC: 5055983. DOI: 10.1155/2016/7432797. View

Zelniker T, Wiviott S, Raz I, Im K, Goodrich E, Bonaca M . SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2018; 393(10166):31-39. DOI: 10.1016/S0140-6736(18)32590-X. View

10.

Pernicova I, Korbonits M . Metformin--mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol. 2014; 10(3):143-56. DOI: 10.1038/nrendo.2013.256. View

11.

Sakalihasan N, Michel J, Katsargyris A, Kuivaniemi H, Defraigne J, Nchimi A . Abdominal aortic aneurysms. Nat Rev Dis Primers. 2018; 4(1):34. DOI: 10.1038/s41572-018-0030-7. View

12.

Rolin S, Dogne J, Michaux C, DELARGE J, Masereel B . Activity of a novel dual thromboxane A(2)receptor antagonist and thromboxane synthase inhibitor (BM-573) on platelet function and isolated smooth muscles. Prostaglandins Leukot Essent Fatty Acids. 2001; 65(2):67-72. DOI: 10.1054/plef.2001.0290. View

13.

Dogne J, Hanson J, de Leval X, Kolh P, Tchana-Sato V, de Leval L . Pharmacological characterization of N-tert-butyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects.... J Pharmacol Exp Ther. 2004; 309(2):498-505. DOI: 10.1124/jpet.103.063610. View

14.

DeRoo E, Stranz A, Yang H, Hsieh M, Se C, Zhou T . Endothelial Dysfunction in the Pathogenesis of Abdominal Aortic Aneurysm. Biomolecules. 2022; 12(4). PMC: 9030795. DOI: 10.3390/biom12040509. View

15.

Zhou Y, Jiang Z, Lu H, Xu Z, Tong R, Shi J . Recent Advances of Natural Polyphenols Activators for Keap1-Nrf2 Signaling Pathway. Chem Biodivers. 2019; 16(11):e1900400. DOI: 10.1002/cbdv.201900400. View

16.

Salmon M . NADPH Oxidases in Aortic Aneurysms. Antioxidants (Basel). 2022; 11(9). PMC: 9495752. DOI: 10.3390/antiox11091830. View

17.

Yoshimura K, Aoki H, Ikeda Y, Fujii K, Akiyama N, Furutani A . Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat Med. 2005; 11(12):1330-8. DOI: 10.1038/nm1335. View

18.

Kumar S, Boon R, Maegdefessel L, Dimmeler S, Jo H . Role of Noncoding RNAs in the Pathogenesis of Abdominal Aortic Aneurysm. Circ Res. 2019; 124(4):619-630. PMC: 6440479. DOI: 10.1161/CIRCRESAHA.118.312438. View

19.

Atturu G, Brouilette S, Samani N, London N, Sayers R, Bown M . Short leukocyte telomere length is associated with abdominal aortic aneurysm (AAA). Eur J Vasc Endovasc Surg. 2010; 39(5):559-64. DOI: 10.1016/j.ejvs.2010.01.013. View

20.

Fujimura N, Xiong J, Kettler E, Xuan H, Glover K, Mell M . Metformin treatment status and abdominal aortic aneurysm disease progression. J Vasc Surg. 2016; 64(1):46-54.e8. PMC: 4925242. DOI: 10.1016/j.jvs.2016.02.020. View